The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000533392
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
12/03/2026
Date registered
Help: Date registered
30/04/2026
Date last updated
Help: Date last updated
11/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
30/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase 1 Randomized, Double-blind, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease
Scientific title
A Phase 1 Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Study to Assess the Safety, Tolerability, and Pharmacokinetics of MTX-439 in Healthy Adults and Adults With Diabetic Kidney Disease
Additional trial identifiers [1] 316765 0
MTX-439-K101
Additional trial identifiers [2] 316849 0
NCT07473323
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Diabetic Kidney Disease 341067 0
Chronic Kidney Disease 341068 0
Condition category
Condition code
Renal and Urogenital 337191 337191 0 0
Kidney disease
Metabolic and Endocrine 337310 337310 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a randomized, double-blind, placebo-controlled, single-ascending dose (SAD) and multiple-ascending dose (MAD) study to assess the safety, tolerability, and PK of single- and multiple-ascending doses of MTX-439 administered in healthy adults and adults with DKD (Diabetic Kidney Disease).
The SAD portion of the study with healthy participants will consist of 5 planned intravenous (IV) dosing cohorts, comprising 8 participants. Dosing will be weight based, and the starting dose will be 100 fold below the top of the safety window (1 mg/kg). Doses will then be increased, depending on the safety, tolerability and drug exposure levels, in subsequent Cohorts, with increases proceeding in either 2x or 3x increments. The exact doses are yet to be determined. Planned doses may be adjusted in response to the data after a cohort-by-cohort safety review committee meeting. Additional participants and/or additional dosing cohorts may be added as needed based on the data. Within each Healthy Participant (HP) cohort, participants will be randomly assigned to receive MTX-439 or matched placebo. The first 2 participants (sentinel participants) within each HP cohort will be randomized 1:1 to receive MTX-439 or placebo on Day 1. These participants will be monitored for 24 hours and, after review of the safety data from both participants and approval by the study Investigator, Medical Monitor, and Sponsor's Responsible Medical Officer (SRMO), the additional 6 participants will be randomized to study drug (n=5 MTX-439; n=1 placebo).
In addition, a minimum of 2 planned IV dosing cohorts comprising 8 DKD participants will receive MTX439 or matched placebo to assess the PK in patients vs healthy controls. DKD Cohort 1 may be dosed any time after the dose escalation meeting for HP Cohort 2 is completed, and the decision is made to dose escalate. The starting dose of study drug in DKD Cohort 1 will be the same as the dose for Cohort 1 in healthy volunteers. No dose can be administered to DKD participants until the same or higher dose has been safely administered to healthy participants. Participants in the DKD SAD portion of the study will be randomized 3:1 to receive MTX-439 or matched placebo on Day 1. Sentinel dosing will not be required in DKD cohorts.
The MAD portion of the study will consist of 4 planned IV dosing cohorts comprising 8 healthy participants (n=6 MTX-439; n=2 placebo). Participants from the SAD portion of the study will not be permitted to participate in the MAD portion of the study, Dosing for each MAD cohort is planned for Day 1, Day 15 and Day 29. Cohort 1 of the MAD portion of the study can begin following completion of the SAD Cohort 2 safety meeting and once the study Investigator, Medical Monitor, and SRMO decide to proceed to HP SAD Cohort 3. Dose escalation will occur depending on the safety, tolerability and PK in previous cohorts.
Participants will be in the study will be followed for safety and be assessed for PK and immunogenicity. For SAD cohorts, participation will be 85 days and for MAD cohorts 113 days.
Intervention code [1] 333451 0
Treatment: Drugs
Description of the comparator or control
Matching Placebo - 0.9% NaCl (Normal Saline) or 5% Dextrose (D5W)-- Use of Normal saline vs. D5W is site/participant dependent, Placebo will be used in both the MAD and SAD portions of the study.
Control group
Placebo

Outcomes
Primary outcome [1] 344704 0
Incidence of Dose-Limiting Toxicities (DLTs)
Timepoint [1] 344704 0
Continuously from first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts
Primary outcome [2] 344705 0
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Timepoint [2] 344705 0
Continuously from first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts
Primary outcome [3] 344706 0
Incidence of Treatment-Related Adverse Events (TRAEs)
Timepoint [3] 344706 0
Continuously from first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts
Secondary outcome [1] 458946 0
Number and percentage of participants requiring dose interruption, dose reduction, or permanent discontinuation of study intervention due to adverse events (Composite).
Timepoint [1] 458946 0
Continuously from first dose up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts
Secondary outcome [2] 458947 0
Change From Baseline in Total SMOC2 Levels, Change from Baseline in circulating total SMOC2 levels following administration of MTX-439
Timepoint [2] 458947 0
Baseline up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts
Secondary outcome [3] 458948 0
Change From Baseline in Free SMOC2 Levels Change from Baseline in circulating free SMOC2 levels following administration of MTX-439.
Timepoint [3] 458948 0
Baseline up to Day 85 for SAD cohorts and up to Day 113 for MAD cohorts

Eligibility
Key inclusion criteria

Main Criteria for Inclusion

All genders, ages 18 to 65 years, inclusive.

Able to read and understand the study and all related materials (including the informed consent form [ICF]), and provide a signed, written informed consent.

Willing and able to complete all protocol-required study visits and procedures.

Participants are required to follow specific contraception measures

DKD participants:

All of the above

Well-controlled diabetes requiring minimal dose adjustments of antidiabetic medications in the past 3 months and no adjustments within 30 days of Screening

Haemoglobin A1C <9.5%

Estimated glomerular filtration rate (eGFR) between 30 and 60

Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Healthy volunteers
Yes
Key exclusion criteria

Main Criteria for Exclusion

Any active medical condition determined clinically significant by the Investigator, except for DKD (for DKD participants).

Body mass index (BMI) >32 kg/m2 for the healthy participant cohort; >40 kg/m2 for the DKD participant cohort.

Use of any systemic immunosuppressant medications, medications to treat diabetes (except DKD participants), antipsychotics, anticoagulants, or other prescription medications other than contraceptives, within 90 days of Screening.

Cancer or a history of cancer or lymphoproliferative disorder within 5 years of Screening except for adequately treated non-melanoma cancers of the skin and cervical carcinoma in situ.

Current infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).

Currently pregnant, lactating, or planning to conceive or contribute to pregnancy.

History of severe depression, psychosis, or suicidal ideation, as determined by the Investigator, within 5 years of Screening.

Any clinically significant disease or laboratory abnormality detected at Screening, including diabetes mellitus, that might interfere with a participant’s ability to complete the study, on study evaluations, or participant safety. Including any clinically significant abnormality on Screening ECGs.

Known allergy to MTX-439 or any of its excipients.


Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC

Funding & Sponsors
Funding source category [1] 321363 0
Commercial sector/Industry
Name [1] 321363 0
Mediar Therapeutics
Country [1] 321363 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
Mediar Therapeutics
Address
Country
United States of America
Secondary sponsor category [1] 324103 0
Commercial sector/Industry
Name [1] 324103 0
ProPharma Group
Address [1] 324103 0
Country [1] 324103 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319898 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 319898 0
Ethics committee country [1] 319898 0
Australia
Date submitted for ethics approval [1] 319898 0
02/03/2026
Approval date [1] 319898 0
23/04/2026
Ethics approval number [1] 319898 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148766 0
Mrs Julia Marshall
Address 148766 0
Doherty Clinical Trials, 2 St Andrews Pl, East Melbourne VIC 3002
Country 148766 0
Australia
Phone 148766 0
+61 3 9970 4200
Fax 148766 0
Email 148766 0
Contact person for public queries
Name 148767 0
Julia Marshall
Address 148767 0
Doherty Clinical Trials, 2 St Andrews Pl, East Melbourne VIC 3002
Country 148767 0
Australia
Phone 148767 0
+61 3 9970 4200
Fax 148767 0
Email 148767 0
Contact person for scientific queries
Name 148768 0
Jeffrey Bornstein
Address 148768 0
Mediar Therapeutics, 201 Brookline Ave, Suite 1002, Boston, MA, 02215
Country 148768 0
United States of America
Phone 148768 0
+1 617 936 0960
Fax 148768 0
Email 148768 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.